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Frontotemporal lobar degeneration (FTLD) includes a spectrum of disorders
characterized by changes of personality and social behavior and, often, a gradual
and progressive language dysfunction. In the last years, several efforts have been
fulfilled in identifying both genetic mutations and pathological proteins associated with
FTLD. The molecular bases undergoing the onset and progression of the disease
remain still unknown. Recent literature prompts an involvement of RNA metabolism in
FTLD, particularly microRNAs (miRNAs). Dysregulation of miRNAs in several disorders,
including neurodegenerative diseases, and increasing importance of circulating miRNAs
in different pathologies has suggested to implement the study of their possible
application as biological markers and new therapeutic targets; moreover, miRNA-based
therapy is becoming a powerful tool to deepen the function of a gene, the mechanism of
a disease, and validate therapeutic targets. Regarding FTLD, different studies showed
that miRNAs are playing an important role. For example, several reports have evaluated
miRNA regulation of the progranulin gene suggesting that it is under their control, as
described for miR-29b, miR-107, and miR-659. More recently, it has been demonstrated
that TMEM106B gene, which protein is elevated in FTLD-TDP brains, is repressed by
miR-132/212 cluster; this post-transcriptional mechanism increases intracellular levels
of progranulin, affecting its pathways. These findings if confirmed could suggest that
these microRNAs have a role as potential targets for some related-FTLD genes. In this
review, we focus on the emerging roles of the miRNAs in the pathogenesis of FTLD.
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INTRODUCTION
Frontotemporal lobar degeneration (FTLD) is a pathological process that represents one of the
main causes of dementia (Cardarelli et al., 2010), after Alzheimer’s Disease (AD), accounting for
5–10% of all dementias and is characterized by atrophy in the frontal and temporal lobes of
the brain (Seltman and Matthews, 2012). At clinical level, FTLD patients manifest personality
and social behavior changes and, often gradual and progressive language dysfunction (McKhann
et al., 2001). Approximately 15% of patients also develop symptoms of motor neuron dysfunction.
Pathologically, around 40% of FTLD patients present with inclusions of hyperphosphorylated
microtubule-associated protein tau (FTLD-tau; Morris et al., 2001), whereas the most FTLD
patients shows ubiquitin-positive inclusions (FTLD-U) constituted mainly by TAR DNA-binding
protein 43 (TDP-43; Neumann et al., 2006). Genetically, several genes are described in association
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to the disease, including microtubule associated protein tau
(MAPT), progranulin (GRN), and C9ORF72. Rare mutations
were also found in genes coding charged multivesicular
body protein 2B (CHMP2B), the valosin-containing protein
(VCP), TAR DNA-binding protein (TARDBP), and FUS (Sieben
et al., 2012). The genetic heterogeneity is further complicated
by possible different clinical manifestations within a single
mutation and even within individual families, suggesting the
involvement of post-transcriptional regulation mechanisms such
as microRNAs (miRNAs).
miRNA BIOGENESIS AND FUNCTIONS
Aberrant RNA processing can cause or exacerbate
neurodegenerative diseases via many mechanisms. Less than
5% of total cellular RNA is messenger RNA coding for proteins,
and the other 95% is non-coding RNAs that has been shown
to have a profound impact on gene expression regulation and
also on other neurochemical processes, and to be implicated as
complexity multipliers in both normal and abnormal conditions
of the human central nervous system (Nelson and Keller, 2007;
Peterson et al., 2009; Rapoport and Nelson, 2011). miRNAs are
members of non-coding RNAs and silence mRNA molecules
via base-pairing with their complementary sequences (Fire
et al., 1998). miRNAs are involved in all development and
pathologic processes targeting protein-coding transcripts mainly
in the 3′UTR (Lytle et al., 2007). The biogenesis of miRNAs is
controlled at temporal and spatial level. miRNAs are composed
of ∼22 nucleotides and produced by two RNase III proteins:
Drosha and Dicer. Indeed, after the transcription, primary
miRNAs (pri-miRNA) undergo to following steps: Drosha
cleaves at the base of a stem to generate ∼60–100 nt hairpin
precursor miRNAs (pre-miRNA; Lee et al., 2003; Denli et al.,
2004); then, pre-miRNA is carried into the cytoplasm by exportin
5 (Exp5) and once in the cytoplasm, it is processed by Dicer,
arising a mature duplex of miRNAs long about 22 bp (Cullen,
2004; Winter and Diederichs, 2011).
FTLD Pathogenically-Related Proteins and
miRNA Biogenesis
TDP-43, one of FTLD pathogenically-related proteins, binds both
DNA and RNA and has multiple functions in mRNAmetabolism
contributing to transcriptional repression, pre-mRNA splicing
and translational regulation (Buratti et al., 2001; Wang et al.,
2008a; Da Cruz and Cleveland, 2011). Interestingly, TDP-43 has
been found in a macromolecular complex containing Drosha and
Dicer (Gregory et al., 2004; Kawahara and Mieda-Sato, 2012).
In addition, TDP-43 binds directly to a subset of pri-miRNAs
to promoting the production of pre-miRNAs (Kawahara and
Mieda-Sato, 2012). FUS, another FTLD pathogenically-related
protein, is a highly conserved RNA/DNA binding protein, as
well. It participates to regulation of gene expression and RNA
processing to the DNA damage response (Wang et al., 2013).
FUS was also found in the macromolecular complex containing
Drosha (Kawahara and Mieda-Sato, 2012) and binding to pri-
miRNAs for miRNA processing (Morlando et al., 2012).
miRNAs IN THE NERVOUS SYSTEM
miRNAs are abundant in the nervous system and show a brain-
specific expression profile correlated to the expression of their
targets. In fact, as suggested by several microarray studies, the
brain expresses a large number of miRNAs that participate in
nervous system physiology (Lagos-Quintana et al., 2002; Miska
et al., 2004; Lim et al., 2005; Manakov et al., 2009). In particular,
they have key roles in the regulation of different biological
functions, as important mediators of plasticity and neurogenesis,
in which they channelize cellular physiology toward neuronal
differentiation.Moreover, they regulate the proliferation and self-
renewal of neural stem cells indirectly influencing neurogenesis
(Stappert et al., 2015). miRNAs are dysregulated in several
neurodegenerative diseases that share a final common pathway
of neuronal cell death. Neurodegeneration includes complex
pathogenic mechanisms; above all, aging is the main risk
factor, but other common characteristics exist among these
pathologies, such as neuroinflammation, protein aggregation,
and mitochondrial dysfunction. Profiling analysis of miRNA
expression in several nervous system disorders identified
signatures correlated with the diagnosis, progression and
prognosis of diseases, and treatment monitoring (Shafi et al.,
2010; Langbaum et al., 2013). The role of specific miRNAs in
a disease has been established in just a few cases and most of
the mechanistic data originates from invertebrate model systems.
In any case, the importance of miRNAs in neurodegenerative
disorders and their emerging role in AD, Parkinson’s disease,
Huntington’s disease, and Amyotrophic lateral sclerosis is
becoming more and more evident. (Kim et al., 2007; Johnson
et al., 2008; Wang et al., 2008b; Nunez-Iglesias et al., 2010; Lukiw
et al., 2012; Grasso et al., 2015). In AD patients, for example,
profiling studies highlighted dramatic changes in several miRNAs
(i.e., miR-29 cluster, miR-107, miR-9, miR-125b, and miR-128;
Delay et al., 2012). Although these alterations under pathological
conditions should be interpreted with caution, they support the
idea that dysregulation of miRNAs is a common mechanism in
neurodegenerative diseases. Consequently, the study of miRNAs
is a novel tool to understanding these diseases and possibly
find therapeutic targets. For a complete coverage of the roles of
miRNAs in other neurodegenerative diseases, we suggest some
recent review articles (Gascon and Gao, 2012; Maciotta et al.,
2013; Grasso et al., 2014; Femminella et al., 2015).
miRNAs AND FTLD
In the last years, several studies have been addressed to
understand the role of miRNAs in the pathophysiology of FTLD.
Two approaches are frequently used to study the involvement of
miRNAs in the pathology. The first is based on a global approach
of miRNA profiling with subsequent validation by RT-qPCR. The
second approach is based on the analysis of miRNAs showing a
direct connection with the disease.
miRNAs Expression Profiling
Kocerha and colleagues decribed an expression profiling study
to identify miRNAs responsive to GRN haploinsufficiency.
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They analyzed the global miRNAs in the frontal cortex of
8 FTLD-TDP patients with GRN mutations and compared
them to a population of 32 FTLD-TDP patients with no
apparent genetic abnormalities (Kocerha et al., 2011). Using
TaqMan Array Human MicroRNA, they identified 20 miRNAs
differentially expressed (P < 0.05) in frontal cortex. Moreover,
a validation study by RT-qPCR analyzes confirmed a differential
expression for 9 of the 20 miRNAs in frontal cortex (miR-
33a∗, let7i∗, miR-516a-3p, miR-548b-5p, miR-548c-5p, miR-565,
miR-571, miR-572, and miR-922). Since these data have not
been functionally validated, the mechanism by which PGRN
haploinsufficiency in FTLD patients leads to altered expression
of these miRNAs is currently unclear and requires future
studies. Moreover, little or nothing has been studied about
the role of these miRNAs in brain or other neurodegenerative
diseases. For example, miR-922 is described as a promoter of tau
phosphorylation by down-regulating ubiquitin carboxy-terminal
hydrolase L1 expression in AD (Zhao et al., 2014), but other
studies are needed to explain their role on neurological disease
pathogenesis.
An expression profiling study was also performed by RNA
deep sequencing in miRNAs derived from well-characterized
brain samples originated from autopsy series at the University
of Kentucky AD Center (UK ADC; Hébert et al., 2013). They
analyzed temporal neocortex gray matter samples of five FTLD
cases, as well as non-demented controls (n = 2), AD (n = 5),
dementia with Lewy bodies (n = 4), hippocampal sclerosis
in aging (n = 4). From a total of 795 miRNAs expressed in
the human brain, they identified 31 human miRNAs differently
expressed. The validation study by miRNA RT-qPCR analysis
reported a down-regulation of miR-132-3p in FTLD cases.
A similar result was obtained by the same authors in AD
patients, as well suggesting that this miRNA could have a more
general function in neurodegeneration than a direct role in
specific subtypes of pathology. Recently, this miRNA was found
participating to a post-transcriptional mechanism that increases
intracellular levels of PGRN, as reported below.
miRNA-132, miR-29b, and miR-659
Regulate GRN Expression
Progranulin (PGRN), encoded by the GRN gene, is a widely
expressed protein involved in the regulation of cell growth and
cell cycle progression (Bateman et al., 1990; He and Bateman,
2003). Mutations in the GRN gene are linked with FTLD (Baker
et al., 2006). Recent findings suggest that GRN is under the
control of miRNAs (Table 1).
miR-132 and miR-132-3p Cluster
miR-132 down-regulation was also recently observed in another
cohort of FTLD-TDP brains (Baker et al., 2006), thus confirming
the data from Hebert and colleagues (He and Bateman, 2003).
This miRNA is a member of the miR-132 cluster (miR-132, miR-
132∗, and miR-212). miR-132 and miR-212 target TMEM106B
through two specific sites in the TMEM106B 3′UTR. Chen
Plotkin and colleagues, having observed increased TMEM106B
expression in FTLD-TDP, supposed a possible upstream role
for miR-132/212. Effectively, they showed first of all that miR-
132 and miR-212 normally repress TMEM106B and then that
they are decreased in FTLD-TDP. Moreover, an involvement
of TMEM106B gene on GRN expression was also observed; in
details, this gene was found to be linked to FTLD-TDP (Van
Deerlin et al., 2010; Van der Zee et al., 2011) and TMEM106B
risk genotypes correlated with decreased plasma progranulin
levels (Finch et al., 2011). Overall, these results suggest a
model in which decreased levels of miR-132/212 carry out to a
higher TMEM106B expression leading to increased TMEM106B
expression and to endosomal-lysosomal dysfunction, which may,
in turn, further increase the levels of TMEM106B, and perturb
PGRN pathways, thereby increasing the risk of developing
FTLD-TDP (Chen-Plotkin et al., 2012).
Further evidence linking miR-132 to FTLD are the reports
addressing its role to the regulate splicing process of the
microtubule associated protein tau gene (Smith et al., 2011;
Hebert et al., 2012) and an involvement in cognitive function in
experimental models including neuronal/synaptic integrity and
the brain’s response to stressors (O’Neill, 2009; Mellios et al.,
2011; Miller et al., 2012; Wanet et al., 2012; Shaltiel et al., 2013;
Bicker et al., 2014).
miR-107
A miRNA assay (RIP-Chip) in neuron-like human cell lines
showed that GRN is a strong target for miR-107 (Wang et al.,
2010). This miRNA recognizes mainly sequence elements in the
open reading frame rather than the 3′UTR of GRN mRNA;
these sequences are highly conserved among vertebrate species.
Wang and colleagues described a down-regulation of miR-
107 in a mouse model of traumatic brain injury, speculating
that this miRNA plays a role in modulating neuronal repair
and regeneration in the mammalian brain through molecular
regulation of GRN and other mRNA targets. Moreover, they
described that miR-107 has also been involved in AD. In
addition, Noren Hooten et al. compared miRNA expression of
blood mononuclear cells in young individuals related to old
individuals by RT-qPCR analysis to test possible aging-related
differences and found that miR-107 was significantly decreased
in aged individuals (Noren Hooten et al., 2010). Taken to in
consideration this evidence, it would be interesting to study the
existence of a possible link between miR-107 expression and
FTLD.
miR-659
Another miRNA regulating GRN expression is miR-659.
Rademakers and colleagues described an allelic variant associated
to FTLD (Rademakers et al., 2008) located in the 3′UTR of GRN
corresponding to a predicted binding site for miR-659. They
described that genotype TT for SNP rs5848 was associated to
FTLD with a 3.2-fold increased risk to develop the pathology
suggesting that a genetic variant in a miRNA binding-site can
influence the risk for FTLD. They further demonstrate that miR-
659 can regulate GRN expression in vitro, with miR-659 binding
more efficiently to the high risk T allele of rs5848. In order to
evaluate the possibility that rs5848 variant is involved in GRN
regulation in patients, they analyzed its expression in FTLD
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TABLE 1 | miRNAs involved in FTLD.
Alterated miRNAs Regulation Target genes Related pathway to FTD References
miR-132/212 Cluster Downregulated in FTLD-TDP
brains
TMEM106B Regulating PGRN levels Chen-Plotkin et al., 2012;
Hébert et al., 2013
miR-107 Downregulated in mice with
cortical traumatic brain injury
GRN Regulating PGRN levels Wang et al., 2010
miR-659 Genetic variant located in the
3′-UTR of GRN within a
miR-659 binding site
GRN Genetic variability in binding-site of
miR-659 can increase the risk for
FTLD
Rademakers et al., 2008
miR-29b – GRN Regulating PGRN levels Jiao et al., 2010
miR-9 and pri-miR-9-2 Downregulated in patient
neurons
Neuronal specification
genes
Neuronal toxicity Zhang et al., 2013
Downregulated in TDP-43
mutants of Drosophila
Li et al., 2013
miR-124 Downregulated in a FTD mouse
model
AMPAR Regulating social behavior Gascon et al., 2014
patient brains revealing an association between GRN lower levels
and the TT genotype. However, other studies are needed to
verify a possible role of miR-659 in the brain and particularly
in FTLD.
miR-29b
Another binding site in the 3′UTR of GRN mRNA was identified
for miR-29b. Indeed, Jiao and colleagues demonstrated that
miR-29b interacts directly with the GRN 3′UTR, regulating
the GRN expression (Jiao et al., 2010). MiR-29b has a role in
neurodevelopment and reach the highest level in adult mouse
brain. Moreover, it is differentially expressed in AD patients
(Hebert et al., 2008), even if to date we do not have evidence about
a regulatory role of this miRNA in FTLD patients. Thus, several
miRNAs may contribute to the pathogenesis of FTLD linked to
progranulin deficiency.
miR-9 and TDP43
As previously reported, TDP-43 has two RNA recognition motifs
and is involved in several roles of RNA metabolism (Da Cruz
and Cleveland, 2011; Lee et al., 2011). Among these, TDP43 has
been associated to miRNA processing; miR-9 is one of these and
is described as an evolutively conserved miRNA, brain-specific
and implicated in some neurodegenerative diseases. A work
published by Zhang and colleagues described a down-regulation
of miR-9 in iPSC-derived neurons (iPSC: induced pluripotent
stem cells) of FTD/ALS patients with TDP-43 mutations; they
explained their results as an a effect of decreased TDP-43
expression revealed in these neurons (Zhang et al., 2013).
Moreover, they found that levels of both pre-miR-9-2 and pri-
miR-9-2 were also reduced, suggesting that miRNA decrease did
not seem to be due to a defect in the miRNA-processing pathway.
Recently, a work on mutant TDP-43 showed an involvement
in FTLD of Drosha protein, one of the most important miRNA
processing molecules involved in the biogenesis of miRNAs.
In this study Drosha increased in correlation with a TDP-43
activation in Neuro 2A cells, leading to hypothesize that a mutant
TDP-43 in FTLD-U, associated with Drosha instability, can
induce neuronal toxicity (Kim et al., 2015). Also in Drosophila,
TDP-43 seems to regulate miR-9a levels by interacting with
pri-miR-9a and likely promoting its stability (Li et al., 2013).
miR-124 and Social Behavioral Deficits
miR-124 is one of most abundant miRNAs in the brain
known to be involved in neuronal development. (Gao, 2010).
Furthermore, it seems to have a role also in neurodegeneration
and in regulating social behavior in FTLD models. Gascon and
colleagues studied a new mouse model of FTLD exhibiting
deficits in sociability (Gascon et al., 2014). They found that
miR-124 is down-regulated in this model causing a dysregulation
in AMPA receptor (AMPAR) composition and a selective
impairment in sociability. Moreover, they examined miR-124
and AMPAR expression in subjects with FTLD, focusing on the
frontal cortex in the subset of cases with bvFTD, whose clinical
presentation is closest to the phenotypes observed in their
mouse model. They found a decrease in miR-124 expression and
a concomitant up-regulation of two AMPAR subunits in the
frontal cortex of bvFTD patients compared with age-matched
controls. Furthermore, they studied miR-124 and AMPARs
in established iPSC lines derived from subjects with bvFTD
(Almeida et al., 2012, 2013), in which the expression of miR-124
and AMPARs in 8-week-old neurons were reduced and some
AMPAR subunit mRNAs upregulated.
Increasing evidences support the presence of common miRNAs
differentially expressed in several neurodegenerative diseases. For
example, miR-132, decreased in FTLD brains, is emerging as
gradually down-regulated during AD at early, mid, and late stages
of disease and showing its important role in the maintenance of
brain integrity (Lau et al., 2014). Another miRNA regulated in
both FTLD and AD is miR-107 that decreases in the temporal
cortex of LOAD patients; in luciferase assays, it showed a
functional interaction with 3′UTR region of BACE1, a protease
involved in the cleavage of APP for the generation of amyloid-
beta (Wang et al., 2008b). miR-107 also controls the expression
of other proteins relevant to AD pathology, such as cofilin
(Yao et al., 2010), an actin-binding protein that accumulates in
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cytoplasmic inclusions. Also miR-29b was found to be alterated
in AD and interacting with BACE, as described by Hebert and
colleagues (Hebert et al., 2008). Moreover, it was hypothesized
that deregulation of miR-29b in the brain was associated to the
increase of apoptotic markers in AD, since miR-29b has been
shown to target a family of pro-apoptotic regulators (Delay et al.,
2012). Then, it could be conceivable the existence of common
miRNAs pathways involved in the molecular mechanisms of
some neurodegenerative diseases.
FINAL REMARKS
In the last years, miRNAs studies are becoming more and
more powerful to understand molecular mechanisms of complex
disorders, such as dementias because they can regulate in fine-
manner the pathways involved in the onset and progression
of the disease and represent molecular tools as biomarkers
and new therapeutic targets. Recent literature prompts that
miRNAs could have an upstream and/or downstream role in the
frontotemporal pathology to regulate a cascade of events leading
to the neurodegeneration.
The studies mentioned in this mini-review provide interesting
clues about miRNAs involvement in the pathology, and even
if rather fragmentary, they could be further deepened by using
high-throughput techniques such as small-RNAseq possibly not
only in patients, but also in cellular and animal models. Several
advances have been performed on the developing of FTLD
models, such as tau and TDP-43 transgenic mice reproducing
some features of FTLD, such as reduced survival, fragmentation
and insolubility of protein aggregates, gliosis, and neuronal loss.
Moreover, iPSCs are likely to become a standard in the field of
neurodegenerative diseases, complementing, but not replacing,
genetic animal models (Ittner et al., 2015). Methodologies
used for miRNAs in FTLD ranged from Northern blotting
to microarrays, but further advances could arrive from small
RNASeq sequencing useful to detect small RNAs from very
low amounts of starting biological material and discovery novel
miRNAs expressed in a specific pathology.
Despite last advances on molecular and pathological bases in
FTLD, the pathology remains still orphan for disease-modifying
therapies. The identification of disease modulating factors will
in turn ameliorate the knowledge of FTLD molecular pathways
opening, in the future, to new therapeutic strategies.
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